KOL Perspectives: Impact of guidelines on the use of Therapeutic Drug Monitoring strategies in IBD
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
› The briefing includes analysis of KOL opinion on the following topic areas:
– Current extent and nature of TDM-based strategies in clinical practice
– Impact of AGA guidelines on TDM on clinical practice
– Unaddressed issues in the AGA guidelines
– Strategies to increase the use of TDM-based strategies in clinical practice
Scope
› The insight briefing is based on Sociable Pharma’s analysis of primary research with our IBD key opinion leaders (KOLs)
› In total, we conducted interviews with 10 KOLs:
– Five Europe-based & five N. America (NA)-based
– Interviews performed during June, 2017
> KOL data is analyzed to produce:
– Charts summarizing KOL opinions
– Chart call-outs of key information & details
– KOL quotes
– Summary of KOL reporting trends
– Insight from Sociable Pharma's analysts
Key Highlights
By enhancing the evidence base for proactive TDM, companies may be able to encourage physicians to override the current AGA recommendations which only support use of reactive TDM in clinical practice
In order to reduce the disparity in frequency of TDM between non-TNFs and anti-TNF therapies in clinical practice, companies marketing non-TNFs should continue to ramp up the availability of data supporting TDM for their products and also investigate strategies to improve access to non-TNF TDM assays
Demonstration of the long-term clinical benefits of proactive & reactive TDM (vs. clinical adjustments) in addition to the provision of improved TDM related therapy-support programs would help strengthen physician confidence in this treatment strategy
Reasons to Buy
Combines Qualitative & semi-quantitative insight from key opinion leaders on " Impact of guidelines on the use of Therapeutic Drug Monitoring strategies in IBD "
Includes insight & recommendations from our disease-specific healthcare analysts
Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of IBD
Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion
Table of Contents
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.